GE HealthCare Reports Q3 Revenue of $5.1 Billion, Net Income of $446 Million
Reuters
Oct 29, 2025
GE HealthCare Reports Q3 Revenue of $5.1 Billion, Net Income of $446 Million
GE HealthCare Technologies Inc. reported third quarter 2025 revenues of $5.1 billion, representing a 6% increase on a reported basis and a 4% rise on an organic basis compared to the prior year. Revenue growth was attributed to performance in the EMEA region and the United States. Total company book-to-bill was 1.06 times, while total company orders increased 6% organically year-over-year. Net income attributable to GE HealthCare was $446 million, down from $470 million in the previous year. Adjusted EBIT for the quarter was $761 million, compared to $795 million a year earlier. Net income margin was 8.7%, down 100 basis points from 9.7%, and Adjusted EBIT margin was 14.8%, down 150 basis points from 16.3%. The margin declines were influenced by tariffs, partially offset by benefits from volume and price.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251029784820) on October 29, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.